Nasdaq · Healthcare

Barinthus Biotherapeutics plc. (BRNS)

As-reported financials and recent SEC filings for Barinthus Biotherapeutics plc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

Net income

$-66.4M

Net margin

—

Diluted EPS

$-1.64

ROE

-89.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$0	$15.0M	$802,000	$44.7M	$268,000
Gross profit	—	—	—	—	—
Operating income	$-70.6M	$-68.0M	$-83.9M	$-4.0M	$-45.2M
Net income	$-66.4M	$-61.1M	$-73.3M	$5.3M	$-50.9M
Diluted EPS	$-1.64	$-1.55	$-1.91	$0.14	$-1.96

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-02

ARS2026-06-10

DEF 14A2026-06-10

8-K2026-05-21

32026-05-01

10-Q2026-04-30

8-K2026-04-30

DEFM14A2026-04-30

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on BRNS

Search Barinthus Biotherapeutics plc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.